Oracle's overall revenue increased 22% year over year in the fiscal third quarter, which ended on Feb. 28, according to a statement. Net income rose to $3.72 billion, or $1.27 a share, from $2.94 ...

Oracle shares surged about 12% on Wednesday after the software giant's upbeat revenue forecast eased concerns over its hefty ...

Shares of Oracle (ORCL) jumped about 9% on Wednesday after the IT giant reported fiscal third-quarter results and guidance that topped Wall Street's estimates. In light of this, below is a list of ...

Oracle on Tuesday predicted that the AI data ​center boom will power its revenue above Wall Street estimates well into 2027, sending its shares up 8.3% in extended trading.

Live Updates Conference Call Highlights 18 hours ago Here’s the key highlights from Oracle’s conference call: First 20/20 ...

While Oracle has traditionally been viewed as a legacy database provider, its aggressive pivot toward Oracle Cloud ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...

Free cash flow at the enterprise software giant has tumbled over the past year as the company races to spend $50 billion on ...

The chip cycle is moving so fast that even the biggest infrastructure deals can’t keep up.” That line from CNBC’s Deirdre Bosa captures the core tension now rattling AI infrastructure investors.